Roche's wholly owned subsidiary Bluefin Merger Subsidiary, Inc. has accepted for payment all shares of 89bio, Inc. that were validly tendered and not withdrawn in its tender offer, representing approximately 60.49% of 89bio's outstanding common stock. Shareholders who tendered received $14.50 per share in cash, plus a non-tradeable contingent value right $(CVR)$ for potential milestone payments of up to $6.00 per share. Roche intends to finalize the acquisition of 89bio through a merger, after which 89bio will become a wholly owned subsidiary of Roche and its shares will no longer be traded on the Nasdaq Global Market.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001135858-en) on October 30, 2025, and is solely responsible for the information contained therein.